Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06628778 · ClinicalTrials.gov registry record · Phase 3
Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).
A Phase 3 study, sponsored by Johns Hopkins All Children's Hospital.
- Not yet
- Registry status
- Phase 3
- Development phase
- 802
- Enrollment target
NCT06628778: Clinical Trial Phase 3 study, sponsored by Johns Hopkins All Children's Hospital.
NCT06628778 is a Phase 3 study that has not yet begun recruiting, run by Johns Hopkins All Children's Hospital. The registered enrollment target is 802 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06628778, a Phase 3 study, has not yet begun recruiting, sponsored by Johns Hopkins All Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 802 participants
- Enrollment target
Study Summary
Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.
Primary Outcome
International Society on Thrombosis and Haemostasis (ISTH) defined symptomatic venous thromboembolism
Interventions
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 802 participants |
| Start Date | 2027-04-15 |
| Est. Completion | 2035-04-15 |
| Phase | Phase 3 |
What is known before NCT06628778 opens enrollment
NCT06628778 is an interventional study that assigns participants to a tested intervention. The registered 802 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin is the first listed.
NCT06628778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06628778 about?
NCT06628778 is a clinical study titled "Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).". Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perfor...
What is the current status of trial NCT06628778?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 802 participants. The study started on 2027-04-15. Estimated completion is 2035-04-15.
What interventions are being tested in trial NCT06628778?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT06628778?
This trial is sponsored by Johns Hopkins All Children's Hospital, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06628778's enrollment target sits among peer trials
802 413th of 2000 higher than 1,587 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI